Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.49 |
| ▸ | MET | P08581 | 3/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.40 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1953680 | 0.88 | MET (0.52) | KDRMETRAB9ANPC1GRM5 | |
| SCHEMBL13810669 | 0.85 | CLK1 (0.48) | MET | |
| SCHEMBL13810667 | 0.83 | KDR (0.53) | KDRMETCYP11B1CYP11B2RAB9A | |
| SCHEMBL13810663 | 0.83 | MET (0.68) | METL3MBTL1GRM5 | |
| SCHEMBL13810665 | 0.80 | SMN1; SMN2 (0.48) | METLTA4HGAARAB9ANPC1 | |
| SCHEMBL11819224 | 0.72 | LTA4H (0.80) | LTA4HRAB9ANPC1SMN1; SMN2TDP1 | |
| SCHEMBL9924384 | 0.70 | MET (0.65) | METCYP11B1CYP11B2RAB9ANPC1 | |
| SCHEMBL17450971 | 0.69 | CYP11B1 (0.54) | LTA4HCYP11B1CYP11B2RAB9ANPC1 | |
| SCHEMBL13810670 | 0.69 | MET (0.48) | KDRMETCYP11B1CYP11B2 | |
| SCHEMBL2698497 | 0.69 | MET (0.70) | KDRMETLTA4HRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156617-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2009-06-18 | — | — | US | disclosed |
| US-20090156617-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156617-A1 | Tyrosine kinase inhibitors | ABL1, ERBB2, MET | KDR 119/4885MET 3/4885LTA4H 4313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.